px Scrolled

Omni One Files U.S. Patent on Diabetain™

Novi, Michigan — Omni One, LLC, with the support of Michigan Business Accelerator Fund (BAF), has filed a U.S. patent with 26 claims on its product Diabetain™, titled “Nutriceutical combination for prevention and treatment of Type 2 diabetes” on August, 18, 2014. The documents were prepared by its attorneys at Butzel Long based in Detroit, Michigan.

Diabetain is the only herbal diabetes-specific supplement designed and formulated by a pharmacist and studied in two separate clinical trials in the U.S. Diabetain reduces fasting blood glucose and A1c (a three months glucose management track indicator) and it will be launched in 2015.  The rights granted by a U.S. patent extent throughout the territory of the United States and a PCT filing generally has the same effect as a regular national patent application in each PCT-member countries once additional documents filed and fees paid in each countries within 18 months.

Butzel Long is a leading law firm with offices located in Michigan, New York City, Washington D.C. and alliance offices in Mexico and China. Founded in 1854, Butzel Long is one of the oldest firms in the Midwest having played a prominent role in the development and growth of several major industries business leaders has turned to it for highly effective legal counsel for over 155 years.

Omni One, LLC is a Novi-based Michigan company, which has a comprehensive product pipeline in the field of alternative diabetes management and related diseases.

For more information about this news release contact Charles Liu, at 248-921-1393 or cliu@diabetainc.com.